Report overview
Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.6 billion by 2025 Says, .Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.
This report contains market size and forecasts of Urological Cancer Therapeutics Drugs in global, including the following market information:
Global Urological Cancer Therapeutics Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Urological Cancer Therapeutics Drugs Market Sales, 2017-2022, 2023-2028, (K MT)
Global top five Urological Cancer Therapeutics Drugs companies in 2021 (%)
The global Urological Cancer Therapeutics Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Xofigo (radium Ra 223 dichloride) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Urological Cancer Therapeutics Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Urological Cancer Therapeutics Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Urological Cancer Therapeutics Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Urological Cancer Therapeutics Drugs Market Segment Percentages, by Type, 2021 (%)
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Global Urological Cancer Therapeutics Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Urological Cancer Therapeutics Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Medical Research Laboratory
Others
Global Urological Cancer Therapeutics Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Urological Cancer Therapeutics Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Urological Cancer Therapeutics Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Urological Cancer Therapeutics Drugs revenues share in global market, 2021 (%)
Key companies Urological Cancer Therapeutics Drugs sales in global market, 2017-2022 (Estimated), (K MT)
Key companies Urological Cancer Therapeutics Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
